

Table S4. Serious violation rulings in the UK and Sweden 2004-2012: promoted drugs

| Therapeutic class by ATC Code | UK^a n=110 | SWE n=101 | Total n=211 |
|--|-----------------------------|------------------|--------------------|
| A02 Drugs for acid related disorders | 3 (2.7%) | 3 (3.0%) | 6 (2.8%) |
| A07 Antidiarrheals | 1 (0.9%) | 0 | 1 (0.5%) |
| A08 Antiobesity preparations | 4 (3.6%) | 4 (4.0%) | 8 (3.8%) |
| A10 Drugs used in diabetes | 15 (14%) | 6 (5.9%) | 21 (10%) |
| A11 Vitamins | 0 | 1 (1.0%) | 1 (0.5%) |
| A12 Mineral supplements | 1 (0.9%) | 0 | 1 (0.5%) |
| A16 Other alim. tract and metabol. products | 1 (0.9%) | 0 | 1 (0.5%) |
| B01 Antithrombotic agents | 4 (3.6%) | 1 (1.0%) | 5 (2.4%) |
| B02 Antihemorrhagics | 0 | 1 (1.0%) | 1 (0.5%) |
| B03 Antianemic preparations | 4 (3.6%) | 1 (1.0%) | 5 (2.4%) |
| C01 Cardiac therapy | 0 | 1 (1.0%) | 1 (0.5%) |
| C05 Vasoprotectives | 1 (0.9%) | 0 | 1 (0.5%) |
| C07 Beta blocking agents | 1 (0.9%) | 0 | 1 (0.5%) |
| C09 Agents act. on renin-angiotensin syst. | 3 (2.7%) | 6 (5.9%) | 9 (4.3%) |
| C10 Lipid modifying agent | 8 (7.2%) | 0 | 8 (3.8%) |
| D03 Prepar. for treatment of wounds/ulcers | 0 | 1 (1.0%) | 1 (0.5%) |
| D10 Anti-acne preparations | 1 (0.9%) | 0 | 1 (0.5%) |
| D11 Other dermatological preparations | 0 | 1 (1.0%) | 1 (0.5%) |
| G03 Sex horm. and modul. of genital syst. | 3 (2.7%) | 6 (5.9%) | 9 (4.3%) |
| G04 Urologicals | 6 (5.5%) | 13 (13%) | 19 (9.0%) |
| J01 Antibacterials for systemic use | 0 | 1 (1.0%) | 1 (0.5%) |
| J02 Antimycotics for systemic use | 2 (1.8%) | 1 (1.0%) | 3 (1.4%) |
| J06 Immune sera and immunoglobulins | 0 | 1 (1.0%) | 1 (0.5%) |
| J07 Vaccines | 1 (0.9%) | 6 (5.9%) | 7 (3.3%) |
| L01 Antineoplastic agents | 4 (3.6%) | 5 (5.0%) | 9 (4.3%) |
| L02 Endocrine therapy | 2 (1.8%) | 0 | 2 (0.9%) |
| L03 Immunostimulants | 2 (1.8%) | 1 (1.0%) | 3 (1.4%) |
| L04 Immunosuppressants | 0 | 7 (6.9%) | 7 (3.3%) |
| M01 Anti-inflamm. and antirheumatic prod. | 3 (2.7%) | 6 (5.9%) | 9 (4.3%) |
| M03 Muscle relaxants | 8 (7.2%) | 0 | 8 (3.8%) |
| M05 Drugs for treatment of bone diseases | 1 (0.9%) | 2 (2.0%) | 3 (1.4%) |
| N01 Anesthetics | 2 (1.8%) | 1 (1.0%) | 3 (1.4%) |
| N02 Analgesics | 8 (7.2%) | 8 (7.9%) | 16 (7.6%) |
| N03 Antiepileptics | 1 (0.9%) | 1 (1.0%) | 2 (0.9%) |
| N04 Anti-parkinson drugs | 1 (0.9%) | 2 (2.0%) | 3 (1.4%) |
| N05 Psycholeptics | 2 (1.8%) | 1 (1.0%) | 3 (1.4%) |
| N06 Psychoanaleptics | 1 (0.9%) | 5 (5.0%) | 6 (2.8%) |
| N07 Other nervous system drugs | 4 (3.6%) | 4 (4.0%) | 8 (3.8%) |
| R03 Drugs for obstructive airway diseases | 2 (1.8%) | 3 (3.0%) | 5 (2.4%) |
| R05 Cough and cold preparations | 1 (0.9%) | 1 (1.0%) | 2 (0.9%) |
| S01 Ophthalmologicals | 0 | 1 (1.0%) | 1 (0.5%) |
| V03 All other therapeutic products | 1 (0.9%) | 0 | 1 (0.5%) |
| no drug | 12 (11%) | 0 | 12 (5.7%) |

^a A few UK cases involved multiple drugs